Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Lumos Pharma, Inc. (LUMO)

7.33   0.08 (1.1%) 06-26 23:18
Open: 7.42 Pre. Close: 7.25
High: 7.6 Low: 7.25
Volume: 6,049 Market Cap: 61(M)
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.6 - 7.63 7.63 - 7.65
Low: 7.18 - 7.21 7.21 - 7.24
Close: 7.28 - 7.32 7.32 - 7.37

Technical analysis

as of: 2022-06-24 4:41:27 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 8.97     One year: 9.82
Support: Support1: 6.51    Support2: 5.41
Resistance: Resistance1: 7.68    Resistance2: 8.4
Pivot: 7.17
Moving Average: MA(5): 7.05     MA(20): 7.3
MA(100): 8.63     MA(250): 8.67
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 38.5     %D(3): 29.5
RSI: RSI(14): 48.5
52-week: High: 11.52  Low: 6.15
Average Vol(K): 3-Month: 14 (K)  10-Days: 11 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LUMO ] has closed below upper band by 40.6%. Bollinger Bands are 3.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sun, 26 Jun 2022
Finnair Plus Status Match for Eurobonus, Flying Blue & Miles&More Members - LoyaltyLobby

Thu, 23 Jun 2022
Lorry smashes through stone wall and crashes onto rail tracks in East Lothian disrupting cross-border LNER and LUMO trains - STV News

Mon, 20 Jun 2022
Rail strikes: Which trains are still running during RMT strike action? -

Thu, 16 Jun 2022
I tried to eat and drink my way into making a profit from a first class train ticket - The Tab

Wed, 15 Jun 2022
Insiders who bought in the last 12 months lose an additional US$7.7k as Lumos Pharma, Inc. (NASDAQ:LUMO) drops to US$56m - Simply Wall St

Tue, 07 Jun 2022
Managing Director of both Lumo and Hull Trains appointed - Railway Gazette

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 8 (M)
% Held by Insiders 5.04e+006 (%)
% Held by Institutions 33.4 (%)
Shares Short 21 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.107e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -13
Return on Assets (ttm) 629.1
Return on Equity (ttm) -17.1
Qtrly Rev. Growth 230000
Gross Profit (p.s.) 489.13
Sales Per Share -32.19
EBITDA (p.s.) 250000
Qtrly Earnings Growth -3.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.23
Price to Cash Flow 0.59

Stock Dividends

Dividend 0
Forward Dividend 18230
Dividend Yield 0%
Dividend Pay Date 2020-03-18
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.